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Abstract
Background Fixed-dose combinations of hypertensive
drugs have been advocated as a suitable option for hyper-
tensive patients who require two or more drugs to achieve
blood pressure (BP) targets.
Objectives Our objective was to assess the efficacy and
safety of lercanidipine/enalapril in clinical practice.
Methods This observational study collected data for
patients with hypertension treated by 46 specialists at
clinics across Portugal with lercanidipine/enalapril (10/
20 mg). The primary outcome measure was the reduction
from baseline in systolic BP (SBP) and diastolic BP (DBP).
Results The registry enrolled 315 patients (59.1 % females;
mean age 64.84 ± 12.18 years). Baseline SBP and DBP were
159.11 ± 16.93 and 88.32 ± 12.35 mmHg, respectively. At a
mean 2.88 ± 1.75 months after starting lercanidipine/enala-
pril, the mean change from baseline in SBP and DBP were
-18.08 ± 15.91 and -10.10 ± 11.46 mmHg, respectively
(both p \ 0.001). This corresponded to reductions of 11.4 and
11.3 % in SBP and DBP, respectively. SBP was reduced
independently of sex and age, and DBP was reduced inde-
pendently of sex. The BP control (\140/90 mmHg) rate sig-
nificantly increased from 10.2 % at baseline to 51.0 % after a
mean of 2.88 months of treatment with lercanidipine/enalapril
(p \ 0.001). Adverse effects were seen in only one patient
(0.3 %), who developed a persistent dry cough.
Conclusions Treatment with the fixed-dose combination
lercanidipine/enalapril was associated with significant
reductions in SBP and DBP, and a significant increase in
the BP control rate. This fixed-dose combination has been
shown to effectively reduce BP, generally independently of
age and sex, and with an excellent safety profile.
Key Points
This study was an observational registry enrolling
315 patients treated by 46 specialists in hypertension
clinics across Portugal. Patients received
lercanidipine/enalapril (10/20 mg) fixed-dose
combination (FDC) for *2 months, and efficacy and
safety of the treatment were assessed.
Treatment with lercanidipine/enalapril FDC was
associated with significant reductions from baseline
in systolic and diastolic blood pressure (BP), and
increases in the rate of BP control (\140/90 mmHg).
The lercanidipine/enalapril FDC had an excellent
safety profile in this population, with treatment-
emergent adverse events reported in only one patient.
These results suggest that lercanidipine/enalapril
(10/20mg) FDC is an effective and safe treatment for
the general hypertensive population in Portugal.
On behalf of the CONCEPT Collaborative Group.
The participants in the group are given in the Appendix.
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1 Introduction
It is well recognized that arterial hypertension is a leading
cause of death and disability worldwide [1]. Hypertension
is a significant risk factor for cardiovascular disease,
stroke, peripheral vascular disease, and end-stage renal
disease [2]. The disease prevalence is impressive, with
more than one-quarter of the world’s adult population
having hypertension at present, and it is expected to
increase in future [3].
Reducing blood pressure (BP) has been shown to reduce
the risk of hypertension-associated morbidity and mortality
[4–6]. However, despite the progressive improvements
observed in many countries [7], BP control rates remain
suboptimal [8]. Reasons for not achieving BP targets
include a lack of adherence to or persistence with antihy-
pertensive therapy, often due to the occurrence of adverse
events, the use of drugs that do not target the mecha-
nism(s) of BP elevation in that patient, and monotherapy
being insufficient to control BP [9].
Because there are multiple possible mechanisms of BP
elevation, and the response to a drug may be attenuated by
counter-regulatory responses, two or more antihypertensive
drugs of different classes are often required to achieve BP
control [9, 10]. It has been shown that combination therapy
using antihypertensive drugs with complementary mecha-
nisms of action has additive BP-lowering effects and is
more effective than high-dose monotherapy with the same
drugs [11, 12]. Furthermore, because it allows the use of
lower doses of each drug than monotherapy, and because in
some cases one drug class can attenuate the adverse events
that occur with another, combination therapy is likely to be
better tolerated [9, 11].
A potential disadvantage of combination therapy is the
additional pill burden, particularly in patients taking mul-
tiple medications for comorbidities. Increasing complexity
of dosing has been shown to reduce adherence and per-
sistence with therapy [10, 12, 13]. A strategy to address this
problem is the use of fixed-dose combinations (FDCs),
which simplifies dosing by allowing two or more drugs to
be administered as a single pill. The use of FDCs has been
shown to improve adherence to antihypertensive therapy
and increase BP control rates [6, 12, 14]. In fact, in some
countries, a parallel increase has been noted in BP control
rates and the use of combination therapy for the treatment
of hypertension [15, 16].
There are numerous possible combinations of antihy-
pertensive drugs available as FDCs. The combination of a
calcium channel blocker (CCB) and a modulator of the
renin-angiotensin system (RAS) appears to be a primary
option [6, 17–19]. One such combination is the third-gen-
eration vasoselective dihydropyridine CCB lercanidipine
plus the angiotensin-converting enzyme inhibitor (ACEI)
enalapril, which is available as an FDC. This combination
has been shown to be effective and well tolerated in clin-
ical trials [20–22]. However, there is a lack of data on its
efficacy and tolerability in real-world clinical practice,
where patients’ characteristics are likely to differ from
those included in controlled clinical trials. In this context,
the CONCEPT Collaborative Group (CCG) aimed to
evaluate the efficacy and tolerability of a lercanidipine
10 mg plus enalapril 20 mg FDC in patients with hyper-
tension treated in the non-hospital setting.
2 Methods
2.1 Study Design
The CCG consists of 46 specialists with a particular
interest in cardiovascular diseases (internal medicine and
cardiologists) practicing in private clinics in Portugal who
decided to perform a critical analysis of their clinical
management of private out-of-hospital patients. The CCG
established an observational registry to assess the efficacy
and safety of lercanidipine/enalapril for the treatment of
hypertension. Patient recruitment and assessment took
place during a 6-month period.
2.2 Patients
All patients with hypertension presenting to a CCG mem-
ber’s clinic who were prescribed lercanidipine/enalapril
(10/20 mg) were included in the registry. Patients were
required to be aged 18 years or older and to have been
prescribed the lercanidipine/enalapril FDC as either initial
therapy or after previous antihypertensive treatment due to
issues of efficacy or tolerability with their existing therapy
or because the specialist considered the lercanidipine/
enalapril to be a more suitable treatment than that pre-
scribed by the patient’s general practitioner. Patients were
initially given lercanidipine/enalapril 10/10 mg, with the
dose increased to 10/20 mg from the second clinic visit.
Lercanidipine/enalapril 10/20 mg was given either alone or
in combination with other antihypertensive drugs in order
to achieve a BP target of \140/90 mmHg.
2.3 Assessments
Data were collected at baseline and after approximately
2 months of treatment with lercanidipine/enalapril
10/20 mg. At both consultations, the patients’ weight and
height were measured, and body mass index (BMI) was
calculated in kg/m2. BP was also measured at baseline and
2 months after the patient started treatment with
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lercanidipine/enalapril 10/20 mg. BP measurements were
taken in a supine position and after a 10-min resting period
by an experienced operator using an oscilometric automatic
sphygmomanometer (clinically validated—class A), with
appropriate cuff. Before their appointment, patients were
advised to avoid coffee or tobacco consumption. Three
measurements were taken at each assessment, with a 2-min
interval between each measurement, and the arithmetic
mean was used in the analysis. Adverse events were col-
lected by the specialists who were instructed to report all
situations of interest. For all assessments, a quality check
was performed on a regular basis to ensure adequate
compliance with all the necessary conditions to warrant the
validation of the study.
2.4 Objectives
The primary outcome measure was the reduction in systolic
and diastolic BP (SBP and DBP, respectively) from base-
line after 2 months of treatment with lercanidipine/enala-
pril 10/20 mg. Secondary endpoints included the
proportion of patients achieving BP control, defined as
140/90 mmHg, the number and classes of concomitant
antihypertensive medications at baseline and endpoint
(therapeutic profile), and the incidence of treatment-emer-
gent adverse events after starting treatment with lercanid-
ipine/enalapril.
2.5 Data Management
All data were codified and personally delivered to the study
coordinator (Joa˜o Maldonado), blinding the name and other
means of identifying individual patients. Electronic medi-
cal records for individual patients were not obtained by the
registry coordinating team. A quality analysis of the data
was then performed by the registry coordinators, and all
registries with incoherent or incomplete data were
excluded.
2.6 Ethical Considerations
All procedures followed were in accordance with the eth-
ical standards of the responsible committee on human
experimentation (institutional and national) and with the
Helsinki Declaration of 1975, as revised in 2000. Informed
consent was obtained from all patients included in the
registry.
2.7 Statistical Analysis
The data were entered into a central database and analyzed
using SPSS for Windows, version 17.0. The distribution of
the variables was tested for normality using the Shapiro–
Wilk test and for homogeneity of variance by Levene’s
test. Simple descriptive statistics were used to characterize
the sample and the distribution of variables.
Within-group comparisons were made using the chi-
squared test with Fisher’s correction, for categorical vari-
ables, the Student’s t-test for pairwise samples, or the
Wilcoxon test for quantitative variables with or without
normal distribution.
The criterion for statistical significance used was
p B 0.05 for a confidence interval of 95 %.
3 Results
3.1 Baseline Characteristics
The registry included 315 patients (59.1 % females) who
were treated with lercanidipine/enalapril as first-line ther-
apy or after previous antihypertensive therapy due to lack
of efficacy (n = 283), adverse events (n = 21), or because
their physician considered the FDC to be a more suitable
treatment than that previously prescribed by the patient’s
general practitioner (n = 59). Many patients switched
therapy for more than one reason.
Baseline characteristics are presented in Table 1. The
mean age was 64.84 ± 12.18 years (range 35–93), and the
mean time since the diagnosis of hypertension was
12.28 ± 13.54 years. Baseline SBP and DBP were
159.11 ± 16.93 and 88.32 ± 12.35 mmHg, respectively.
BP was controlled (\140/90 mmHg) in 10.2 % of patients.
Antihypertensive treatments at baseline are shown in
Table 1. The mean number of antihypertensive drugs per
patient at baseline was 2.1 ± 1.3. The most commonly
used antihypertensive classes were diuretics (45.5 % of
patients), ACEIs (40.1 %), angiotensin II receptor antago-
nists (33.7 %), b-blockers (31.9 %), and CCBs (29.3 %).
Free combinations were used in 32.2 % of the patients and
FDCs in 33.4 %.
3.2 Blood Pressure (BP) Reduction and Control Rates
BP was measured at a mean of 2.88 ± 1.75 months after
initiating treatment with lercanidipine/enalapril. Mean
changes from baseline for SBP and DBP were -18.08 ±
15.91 and -10.10 ± 11.46 mmHg (Fig. 1; Table 2;
p \ 0.0001 for both). This corresponded to mean reduc-
tions in SBP and DBP of 11.4 and 11.3 %, respectively,
compared with baseline. The BP control rate significantly
increased from 10.2 % at baseline to 51.0 % after treat-
ment with lercanidipine/enalapril (p \ 0.001) (Fig. 2). SBP
was reduced from baseline, independently of sex and age
(Fig. 1), while DBP was reduced independently of sex;
patients aged \60 years had a significantly greater
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reduction from baseline in DBP than patients aged
C60 years (p = 0.001; Fig. 1). BP control rates in the
analysis by age were similar to those of the overall popu-
lation; control rates before and after treatment in patients
aged \60 years were 4.3 and 51.1 %, while those in
patients aged C61 years were 8.7 and 50 %.
This effect was observed irrespective of whether or not
patients were receiving concomitant antihypertensive
treatment; however, the magnitude of the BP reduction
observed was greater in patients receiving lercanidipine/
enalapril alone compared with patients receiving the FDC
with other antihypertensive drugs (Table 3). These differ-
ences may arise from the fact that patients who received
the FDC alone had higher baseline BP and lower baseline
BP control rates (despite the fact that all patients who
received FDC alone were not antihypertensive treatment
naı¨ve) than those who received the FDC with other anti-
hypertensive drugs (1.9 vs. 11.8 %, respectively;
p = 0.033). By *2 months of treatment with lercanidi-
pine/enalapril, the BP levels were similar between patients
Table 1 Baseline clinical and therapeutic profile of the study population
Total (n = 315) Females (n = 186) Males (n = 129) p value
Age, years 64.84 ± 12.18 65.27 ± 11.82 64.22 ± 12.75 0.48
SBP, mmHg 159.11 ± 16.93 159.64 ± 16.57 161.18 ± 16.94 0.45
DBP, mmHg 88.32 ± 12.35 88.23 ± 11.79 90.19 ± 11.58 0.17
BP \140/90 mmHg 10.2 7.9 7.0 0.82
a-blocker 1.9 2.1 1.6 0.52
ARAII 33.7 35.4 27.1 0.06
b-blocker 31.9 30.8 32.9 0.38
CCB 29.3 30.9 28.7 0.42
ACEI 40.1 42.1 39.7 0.50
Diuretic 45.5 49.4 31.8 0.01
Renin inhibitor 5.4 5.9 4.6 0.40
Free combination 32.2 34.6 20.2 0.23
Fixed-dose combination 33.4 34.5 25.6 0.05
Number of antihypertensive drugs 2.1 ± 1.3 2.09 ± 1.24 1.71 ± 1.26 0.06
All values are mean ± SD or % of patients, unless otherwise stated
ACEI angiotensin-converting enzyme inhibitor, ARAII angiotensin II receptor antagonist, BP blood pressure, CCB calcium-channel blocker, DBP
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*p = 0.001 versus DBP
reduction in patients aged
C60 years. BP blood pressure,
DBP diastolic blood pressure,
SBP systolic blood pressure
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receiving the FDC alone and patients receiving the FDC
with other antihypertensive drugs (141.16 ± 15.06 vs.
140.38 ± 12.10 for SBP; 78.03 ± 12.45 vs. 79.15 ± 8.31
for DBP), as were the control rates (51.5 and 48.1 %).
The magnitude of the BP response was slightly greater
in patients not previously treated with ACEIs and/or CCBs,
as expected, although BP significantly reduced in both
conditions (Table 4). Baseline and post-lercanidipine/ena-
lapril BP levels were similar in both cases.
Finally, there were no significant differences between
the number of concomitant drugs received between the age
groups, although a trend for a lower number was seen in the
younger group (1.7 vs. 2.0, p = not significant).
3.3 Therapeutic Profile
The use of most other classes of antihypertensive medi-
cation decreased slightly from baseline after starting
treatment with lercanidipine/enalapril; only the proportion
of patients receiving an a-blocker (2.2 %) was higher than
at baseline (Fig. 3). All patients were given lercanidipine/
enalapril, and 23.3 % were taking a free combination
regimen; none of the patients received an FDC other than
lercanidipine/enalapril. No patients switched to lercanidi-
pine ? enalapril as a free combination. The mean number
of antihypertensive drugs per patient increased to 2.8 ± 0.9
at a mean of 2.88 months after addition of lercanidipine/
enalapril, although the difference from baseline was not
statistically significant (p = 0.321).
3.4 Tolerability
Treatment with lercanidipine/enalapril was well tolerated.
Treatment-emergent adverse effects occurred in only one
patient (0.3 %), who developed a persistent dry cough after
the initiation of lercanidipine/enalapril treatment. This
cough was considered to be possibly related to treatment
with enalapril. None of the patients developed edema.
4 Discussion
This observational registry study showed that treatment
with a lercanidipine/enalapril FDC was associated with
significant reductions in SBP and DBP and a significant
increase in the proportion of patients achieving BP control
compared with baseline.
The reduction in BP observed in our study was as
expected with combinations of two or more antihyperten-
sive drugs. A meta-analysis by Law et al. [11] found that
the use of two antihypertensive drugs at half-standard doses
produced reductions in SBP and DBP of 13.3 and
7.3 mmHg, respectively; corresponding values for three
drugs at half-standard doses were 19.9 and 10.7 mmHg,
respectively11. Our results are also in agreement with the
well known efficacy of an FDC of a CCB with a modulator
Table 2 Blood pressure levels before and after adding lercanidipine/enalapril fixed-dose combination
Baseline After adding FDC Mean difference (95 % CI) p value
Mean SBP, mmHg 159.11 ± 16.93 141.04 ± 14.60 -18.08 ± 15.91 (-19.84, -16.31) \0.0001
Mean DBP, mmHg 88.32 ± 12.35 78.22 ± 11.86 -10.10 ± 11.46 (-11.37, -8.83) \0.0001
All values are mean ± SD unless otherwise stated










Fig. 2 Blood pressure control rate (a) before (baseline) and (b) after
adding lercanidipine/enalapril 10/20 mg fixed-dose combination
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of the RAS [20], even if we consider the relatively old
population evaluated, and the extended period of treatment
between diagnosis and inclusion in this study. In this
context, the rate of BP control was also impressive, being
observed in 51 % of patients with BP\140/90 mmHg after
a mean of 2.88 months of treatment with the fixed-dose
regimen.
In randomized, controlled phase III trials of lercanidi-
pine/enalapril FDC, reductions in SBP and DBP of 7.7–9.8
and 7.1–9.2 mmHg, respectively, were observed after
12 weeks of treatment [21]. The reductions in SBP and
DBP observed in our study were greater than this (18.08
and 10.10 mmHg, respectively). In these two studies, the
proportion of patients with normalized SBP and DBP was
22–24 % [21]. It should be noted that these studies inclu-
ded only patients who had not achieved BP control with
either lercanidipine or enalapril as monotherapy, and this
could have contributed to the smaller reductions in BP and
lower BP control rates compared with our study. Further-
more, one of these studies used a lower dose of enalapril
(10 mg) than in our study and produced smaller reductions
in SBP and DBP than seen with lercanidipine/enalapril
Table 3 Change in blood pressure levels in patients who received lercanidipine/enalapril fixed-dose combination alone and those who received
the lercanidipine/enalapril in combination with other antihypertensive drugs
Change from baseline Lercanidipine/enalapril alone (n = 52) Lercanidipine/enalapril ? antihypertensives (n = 262) p value
Mean SBP, mmHg -28.52 ± 15.00 -16.00 ± 15.28 \0.0001
Mean DBP, mmHg -9.36 ± 11.89 -13.79 ± 8.05 0.01
All values are mean ± SD unless otherwise stated
DBP diastolic blood pressure, SBP systolic blood pressure
Table 4 Change in blood pressure levels with lercanidipine/enalapril fixed-dose combination treatment in patients who were receiving
angiotensin-converting enzyme inhibitor and/or calcium-channel blocker treatment at baseline compared with patients who were not
Change from baseline with lercanidipine/enalapril treatment Previous ACEI and/or CCB No previous ACEI/CCB p value
Mean SBP, mmHg -16.33 ± 15.73 -20.11 ± 15.93 0.036
Mean DBP, mmHg -8.41 ± 10.73 -12.06 ± 11.99 0.005
All values are mean ± SD unless otherwise stated















































Fig. 3 Therapeutic profile
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152 J. Maldonado et al.
10/20 mg in the second study. It should also be noted that
the patients included in our registry had been receiving
antihypertensive regimens prescribed by general practitio-
ners rather than specialists. It is therefore possible that even
where their initial therapy had shown BP-lowering activity
it may have been suboptimal, and thus further reduction in
BP could be obtained by switching to a more suitable
therapy, in this case the lercanidipine/enalapril FDC.
The population of our registry was relatively old (mean
age approximately 65 years). The age of the study popu-
lation may have meant that there was a higher proportion of
patients with isolated systolic hypertension (ISH) than
would have been seen for a study with a younger popula-
tion. However, baseline BP measurements were averaged,
so it was not possible to determine the proportion of
patients with ISH. Patients with ISH have marked arterial
stiffening, which makes BP control more difficult. In light
of the possibility that a significant proportion of patients in
our study could have had ISH, the BP-lowering and BP
control rates observed are even more impressive. Our
results are comparable to those seen in a study in elderly
patients (age 60–85 years), in which treatment with the
combination of lercanidipine 10 mg plus enalapril 20 mg
for 4 weeks was associated with a reduction in SBP of
16.9 mmHg compared with baseline, and a BP control rate
of 45 % [20].
In this study, the BP-reducing effect of lercanidipine/
enalapril was greater in patients receiving lercanidipine/
enalapril alone compared with patients receiving the FDC
with other antihypertensive drugs. However, at the end of
the study period, the mean BP values and BP control rates
in both patient groups were similar. This can best be
explained by the fact that the magnitude of the therapeutic
benefit is generally correlated with baseline BP values [22].
As the patients who received lercanidipine/enalapril alone
had significantly greater baseline BP values and lower BP
control rates than those who received lercanidipine/enala-
pril with other antihypertensive drugs, the greater magni-
tude of improvement at the end of the study in patients who
received lercanidipine/enalapril alone was expected.
The introduction of this FDC, in addition to the noted
efficacy, did not significantly increase the number of drugs
required to achieve BP control. These results may be par-
ticularly interesting from an economic perspective, as a
reduction in the number of concomitant medications has
the potential to produce cost savings, particularly for a
high-prevalence disease such as hypertension.
The primary limitation of this study was that it was an
open-label pharmaco-epidemiological registry, with all the
inherent limitations and advantages of such a design. Other
limitations were the relatively small number of patients and
the short follow-up duration. The size of the study was
necessarily limited by the number of patients presenting to
CCG members’ clinics during the study period for whom
the lercanidipine/enalapril (10/20 mg) FDC was considered
the most appropriate treatment.
Finally, the extremely low incidence of adverse effects
noted after initiating treatment with the lercanidipine/
enalapril FDC was especially interesting. Despite the
excellent tolerability attributed to the new dihydropyri-
dines, namely with respect to the incidence of ankle edema
[23, 24], it may be surprising that none of the patients
developed edema with lercanidipine in this study. How-
ever, the combination of a CCB with a modulator of the
RAS has been shown to reduce the incidence of such
events, through a well established mechanism [21, 25].
Only a single case of cough was reported in our study, and
this was considered to be possibly related to enalapril as
cough is a known adverse effect of ACEIs [26]. Cough was
the most common adverse event observed in clinical trials
of lercanidipine/enalapril FDC [21]. The incidence of
peripheral edema with the FDC also appears to be low,
with only 1.5 % of patients treated with lercanidipine/
enalapril 10/20 mg for up to 52 weeks in clinical trials
experiencing this adverse event [21].
5 Conclusion
Treatment with an FDC of lercanidipine/enalapril (10/
20 mg) for a mean of 2.88 months was associated with a
significant reduction of SBP and DBP and an increase in
the BP control rate from 10.2 to 51.0 %, relative to base-
line, a result achieved with a reduction in the number of
drugs used. The lercanidipine/enalapril FDC was shown to
effectively reduce BP, generally independently of age and
sex, and with an excellent safety profile.
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Appendix: Participants in the CONCEPT Collaborative
Group
This registry is the result of the commitment and dedication
of a group of 46 specialists with a particular interest in
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cardiovascular diseases, listed below. Paula Gago, Idale´cio
Bernardo, Pedro Miguel Balza, Sanjiva Cadocar, Nuno
Jorge Fonseca, Filipe Seixo, Lurdes Almeida, Marco Au-
re´lio Castro, Pedro Silva Cunha, Hugo Filipe Pego, Fa´tima
Veiga, Luı´s Filipe Pereira, Susana Castela, Carvalho Ro-
drigues, Joa˜o Maria Abecassis, Susana Martins, Grac¸a
Almeida, Omar Zalueta Pereira, Paulo Ramos, Joa˜o
Madeira Lopes, Sı´lvio Leal, Carlos Aguiar, Pedro Von
Haffe, Maria Jose´ Ferreira, Cristina Rodrigues, Isabel
Maria Vilac¸a, Emı´lia Barbosa, Abı´lio Ribeiro, Gonc¸alo
Rocha, Se´rgio Miguel Silva, Manuel Pinto Monteiro, Fer-
nando Santos Reis, Jose´ Bernardes Correia, Joa˜o Porto,
Ana Sofia Teixeira, Rui Provideˆncia, Jose´ Alexandre An-
tunes, Rui Pires, Anto´nio Antunes, Leonel Pinto, Joa˜o
Miguel Santos, Joa˜o Maldonado, Andre´ Paupe´rio, Meireles
Branda˜o, Ma´rio Almeida, Pedro Semedo.
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